[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2740389A1 - Derives de 3-hydroquinazoline-4-one utilises comme inhibiteurs de stearyl-acp desaturase - Google Patents

Derives de 3-hydroquinazoline-4-one utilises comme inhibiteurs de stearyl-acp desaturase Download PDF

Info

Publication number
CA2740389A1
CA2740389A1 CA2740389A CA2740389A CA2740389A1 CA 2740389 A1 CA2740389 A1 CA 2740389A1 CA 2740389 A CA2740389 A CA 2740389A CA 2740389 A CA2740389 A CA 2740389A CA 2740389 A1 CA2740389 A1 CA 2740389A1
Authority
CA
Canada
Prior art keywords
oxo
methyl
hydroquinazolin
dihydroquinazolin
dichlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2740389A
Other languages
English (en)
Inventor
Dmitry Koltun
Eric Parkhill
Melanie Boze
Jeff Zablocki
Natalya Vasilevich
Elena Mayboroda
Andrey Glushkov
Andrew Cole
Jeffrey Chisholm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Ligand Pharmaceuticals Inc
Original Assignee
Gilead Sciences Inc
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Ligand Pharmaceuticals Inc filed Critical Gilead Sciences Inc
Publication of CA2740389A1 publication Critical patent/CA2740389A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2740389A 2008-10-15 2008-10-15 Derives de 3-hydroquinazoline-4-one utilises comme inhibiteurs de stearyl-acp desaturase Abandoned CA2740389A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/079975 WO2010056230A1 (fr) 2008-10-15 2008-10-15 Dérivés de 3-hydroquinazoline-4-one utilisés comme inhibiteurs de stéaryl-acp désaturase

Publications (1)

Publication Number Publication Date
CA2740389A1 true CA2740389A1 (fr) 2010-05-20

Family

ID=40749129

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2740389A Abandoned CA2740389A1 (fr) 2008-10-15 2008-10-15 Derives de 3-hydroquinazoline-4-one utilises comme inhibiteurs de stearyl-acp desaturase

Country Status (4)

Country Link
EP (1) EP2350029A1 (fr)
JP (1) JP2012505881A (fr)
CA (1) CA2740389A1 (fr)
WO (1) WO2010056230A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987257B2 (en) 2011-01-31 2015-03-24 Novartis Ag Heterocyclic derivatives
CA2853256C (fr) 2011-10-28 2019-05-14 Novartis Ag Nouveaux derives de purine et utilisation de ceux-ci dans le traitement d'une maladie
MX2014012992A (es) 2012-04-24 2015-08-14 Chugai Pharmaceutical Co Ltd Derivado de quinazolindiona.
AR090836A1 (es) 2012-04-24 2014-12-10 Chugai Pharmaceutical Co Ltd Derivados de benzamida
EP2941426B1 (fr) * 2012-12-21 2018-06-13 Gilead Calistoga LLC Pyrimidine aminoalkyl-quinazolones substituées en tant qu'inhibiteurs de phosphatidylinositol 3-kinase
US10005739B2 (en) 2013-10-23 2018-06-26 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
IL279830B (en) 2015-02-02 2022-08-01 Forma Therapeutics Inc -Aryl-4-amino-[0,5,4] bicyclic hydroxamic acids as hdac inhibitors
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
EP3472131B1 (fr) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. Acides hydroxamiques de 2-spiro-indan-5-yl ou de 2-spiro-indan-6-yl utilisés en tant qu'inhibiteurs de hdac
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
EP3566055A4 (fr) 2017-01-06 2020-12-02 Yumanity Therapeutics, Inc. Méthodes de traitement de troubles neurologiques
EP3700934A4 (fr) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. Composés et utilisations de ces composés
WO2020154571A1 (fr) 2019-01-24 2020-07-30 Yumanity Therapeutics, Inc. Composés et leurs utilisations
CA3182133A1 (fr) * 2020-06-29 2022-01-06 Council Of Scientific & Industrial Research Derives de quinazolinones pour le traitement de la steatose hepatique non alcoolique, leur preparation et leur utilisation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2020073A1 (fr) * 1989-07-03 1991-01-04 Eric E. Allen Quinazolinones substitues comme antagonistes de l'angiotensine ii
US6638937B2 (en) * 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
EP1804799B1 (fr) * 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et leur utilisation en tant qu'agents thérapeutiques
PL1830869T3 (pl) * 2004-12-24 2013-11-29 Novartis Ag Sposób leczenia lub profilaktyki
WO2006125180A1 (fr) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Derives de piperazine: utilisation comme agents therapeutiques

Also Published As

Publication number Publication date
JP2012505881A (ja) 2012-03-08
EP2350029A1 (fr) 2011-08-03
WO2010056230A1 (fr) 2010-05-20

Similar Documents

Publication Publication Date Title
CA2740389A1 (fr) Derives de 3-hydroquinazoline-4-one utilises comme inhibiteurs de stearyl-acp desaturase
US20080255161A1 (en) 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US8148376B2 (en) 3, 4-dihydroquinoxalin-2(1H)-ones for use as stearoyl CoA desaturase inhibitors
US20100267748A1 (en) HETEROCYCLIC COMPOUNDS USEFUL AS STEAROYL CoA DESATURASE INHIBITORS
US7893066B2 (en) Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
CA2681560A1 (fr) Derives de pteridinone destines a etre utilises comme des inhibiteurs de stearoyl-coa desaturase
US8088792B2 (en) Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors
US20090105283A1 (en) 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20090253704A1 (en) PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
WO2009126527A1 (fr) Dérivés de 2h-benzo[b][1,4]oxazin-3(4h)-one à utiliser comme inhibiteurs de la stéaroyl-coa désaturase
WO2010045374A1 (fr) Dérivés de 3-hydroquinazoline-4-1 à utiliser comme inhibiteurs de la stéaroyl-coa-désaturase
JP2011516546A (ja) ステアロイル−ＣｏＡデサチュラーゼのインヒビターとして使用するための二環式窒素含有複素環化合物

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20131015